{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:08:25Z","timestamp":1782551305484,"version":"3.54.5"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ijid.2023.09.010","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T15:57:03Z","timestamp":1694879823000},"page":"146-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Virus evolution and reduced viral viability during treatment of persistent COVID-19 Omicron BA.5 infection in an immunocompromised host"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5661","authenticated-orcid":false,"given":"Hiroyasu","family":"Kaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Inasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masae","family":"Itamochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.09.010_bib0001","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.09.010_bib0002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2023.09.010_bib0003","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijid.2022.06.023","article-title":"SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient","volume":"122","author":"Quaranta","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2023.09.010_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/v15020291","article-title":"Viral population heterogeneity and fluctuating mutational pattern during a persistent SARS-CoV-2 infection in an immunocompromised patient","volume":"15","author":"Brandolini","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2023.09.010_bib0005","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2072455","article-title":"Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants","volume":"14","author":"Ozawa","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.ijid.2023.09.010_bib0006","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2023.09.010_bib0007","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2023.02.068","article-title":"Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort","volume":"41","author":"Itamochi","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.09.010_bib0008","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.09.010_bib0009","article-title":"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany","volume":"8","author":"Jensen","year":"2021","journal-title":"Lancet Reg Health Eur"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122300721X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122300721X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T22:08:56Z","timestamp":1738793336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197122300721X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":9,"alternative-id":["S120197122300721X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.09.010","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus evolution and reduced viral viability during treatment of persistent COVID-19 Omicron BA.5 infection in an immunocompromised host","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}